Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase I Clinical Trial of GPC3-Targeted Chimeric Antigen Receptor Autologous T-Cell Injection (Super CAR-T) for the Treatment of Patients With Advanced Hepatocellular Carcinoma

NCT07493044 is registered in ClinicalTrials.gov with Guangzhou FineImmune Biotechnology Co., LTD. as lead sponsor.

NCT NCT07493044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07493044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase I Clinical Trial of GPC3-Targeted Chimeric Antigen Receptor Autologous T-Cell Injection (Super CAR-T) for the Treatment of Patients With Advanced Hepatocellular Carcinoma
Lead sponsor
Guangzhou FineImmune Biotechnology Co., LTD.
Phase
Phase 1
Overall status
Recruiting
Start date
March 27, 2026
Completion date
July 30, 2028
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma (hcc), gpc3 positive hepatocellular carcinoma